These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 31348908)

  • 21. Relationship between β-Secretase, inflammation and core cerebrospinal fluid biomarkers for Alzheimer's disease.
    Alcolea D; Carmona-Iragui M; Suárez-Calvet M; Sánchez-Saudinós MB; Sala I; Antón-Aguirre S; Blesa R; Clarimón J; Fortea J; Lleó A
    J Alzheimers Dis; 2014; 42(1):157-67. PubMed ID: 24820015
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Cerebrospinal Fluid Neurogranin/BACE1 Ratio is a Potential Correlate of Cognitive Decline in Alzheimer's Disease.
    De Vos A; Struyfs H; Jacobs D; Fransen E; Klewansky T; De Roeck E; Robberecht C; Van Broeckhoven C; Duyckaerts C; Engelborghs S; Vanmechelen E
    J Alzheimers Dis; 2016 Jul; 53(4):1523-38. PubMed ID: 27392859
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cerebrospinal fluid monoamine metabolite concentrations as intermediate phenotypes between glutamate-related genes and psychosis.
    Andreou D; Söderman E; Axelsson T; Sedvall GC; Terenius L; Agartz I; Jönsson EG
    Psychiatry Res; 2015 Sep; 229(1-2):497-504. PubMed ID: 26142836
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cerebrospinal fluid neurogranin and YKL-40 as biomarkers of Alzheimer's disease.
    Janelidze S; Hertze J; Zetterberg H; Landqvist Waldö M; Santillo A; Blennow K; Hansson O
    Ann Clin Transl Neurol; 2016 Jan; 3(1):12-20. PubMed ID: 26783546
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relationships of Cerebrospinal Fluid Monoamine Metabolite Levels With Clinical Variables in Major Depressive Disorder.
    Yoon HS; Hattori K; Ogawa S; Sasayama D; Ota M; Teraishi T; Kunugi H
    J Clin Psychiatry; 2017; 78(8):e947-e956. PubMed ID: 28749090
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Monoamine metabolites in normal human cerebrospinal fluid and in degenerative diseases of the central nervous system.
    González-Quevedo A; García JC; Fernández R; Fernández Cartaya L
    Bol Estud Med Biol; 1993; 41(1-4):13-9. PubMed ID: 7521168
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Importance and impact of preanalytical variables on Alzheimer disease biomarker concentrations in cerebrospinal fluid.
    Le Bastard N; De Deyn PP; Engelborghs S
    Clin Chem; 2015 May; 61(5):734-43. PubMed ID: 25869575
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Simultaneous determination of DOPAC, MHPG, 5-HIAA and HVA in CSF by direct injection on a liquid chromatograph with coulometric detection.
    d'Eril GV; Rizzo V; Cellerino GP
    Funct Neurol; 1990; 5(2):145-9. PubMed ID: 1699850
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Accuracy of cerebrospinal fluid Aβ1-42 measurements: evaluation of pre-analytical factors using a novel Elecsys immunosassay.
    Rozga M; Bittner T; Höglund K; Blennow K
    Clin Chem Lab Med; 2017 Aug; 55(10):1545-1554. PubMed ID: 28160541
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A targeted proteomic multiplex CSF assay identifies increased malate dehydrogenase and other neurodegenerative biomarkers in individuals with Alzheimer's disease pathology.
    Paterson RW; Heywood WE; Heslegrave AJ; Magdalinou NK; Andreasson U; Sirka E; Bliss E; Slattery CF; Toombs J; Svensson J; Johansson P; Fox NC; Zetterberg H; Mills K; Schott JM
    Transl Psychiatry; 2016 Nov; 6(11):e952. PubMed ID: 27845782
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chitinase-3-like 1 protein (CHI3L1) locus influences cerebrospinal fluid levels of YKL-40.
    Deming Y; Black K; Carrell D; Cai Y; Del-Aguila JL; Fernandez MV; Budde J; Ma S; Saef B; Howells B; Bertelsen S; Huang KL; Sutphen CL; Tarawneh R; Fagan AM; Holtzman DM; Morris JC; Goate AM; Dougherty JD; Cruchaga C
    BMC Neurol; 2016 Nov; 16(1):217. PubMed ID: 27832767
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Simultaneous measurement of monoamine metabolites and 5-methyltetrahydrofolate in the cerebrospinal fluid of children.
    Akiyama T; Hayashi Y; Hanaoka Y; Shibata T; Akiyama M; Nakamura K; Tsuyusaki Y; Kubota M; Yoshinaga H; Kobayashi K
    Clin Chim Acta; 2017 Feb; 465():5-10. PubMed ID: 27940130
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Does Caffeine Consumption Modify Cerebrospinal Fluid Amyloid-β Levels in Patients with Alzheimer's Disease?
    Travassos M; Santana I; Baldeiras I; Tsolaki M; Gkatzima O; Sermin G; Yener GG; Simonsen A; Hasselbalch SG; Kapaki E; Mara B; Cunha RA; Agostinho P; Blennow K; Zetterberg H; Mendes VM; Manadas B; de Mendon A
    J Alzheimers Dis; 2015; 47(4):1069-78. PubMed ID: 26401784
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Study on monoamine metabolite contents of cerebrospinal fluid in patients with neurodegenerative diseases.
    Ichikawa N
    Tohoku J Exp Med; 1986 Dec; 150(4):435-46. PubMed ID: 2436350
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neurotransmitter markers in the cerebrospinal fluid of normal subjects. Effects of aging and other confounding factors.
    Hartikainen P; Soininen H; Reinikainen KJ; Sirviö J; Soikkeli R; Riekkinen PJ
    J Neural Transm Gen Sect; 1991; 84(1-2):103-17. PubMed ID: 1675857
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Contactin-2, a synaptic and axonal protein, is reduced in cerebrospinal fluid and brain tissue in Alzheimer's disease.
    Chatterjee M; Del Campo M; Morrema THJ; de Waal M; van der Flier WM; Hoozemans JJM; Teunissen CE
    Alzheimers Res Ther; 2018 Jun; 10(1):52. PubMed ID: 29859129
    [TBL] [Abstract][Full Text] [Related]  

  • 37. C-terminal neurogranin is increased in cerebrospinal fluid but unchanged in plasma in Alzheimer's disease.
    De Vos A; Jacobs D; Struyfs H; Fransen E; Andersson K; Portelius E; Andreasson U; De Surgeloose D; Hernalsteen D; Sleegers K; Robberecht C; Van Broeckhoven C; Zetterberg H; Blennow K; Engelborghs S; Vanmechelen E
    Alzheimers Dement; 2015 Dec; 11(12):1461-1469. PubMed ID: 26092348
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neurochemical markers in the cerebrospinal fluid of patients with Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis and normal controls.
    Hartikainen P; Reinikainen KJ; Soininen H; Sirviö J; Soikkeli R; Riekkinen PJ
    J Neural Transm Park Dis Dement Sect; 1992; 4(1):53-68. PubMed ID: 1347220
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Proteomic analysis of cerebrospinal fluid extracellular vesicles: a comprehensive dataset.
    Chiasserini D; van Weering JR; Piersma SR; Pham TV; Malekzadeh A; Teunissen CE; de Wit H; Jiménez CR
    J Proteomics; 2014 Jun; 106():191-204. PubMed ID: 24769233
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Monoaminergic Markers Across the Cognitive Spectrum of Lewy Body Disease.
    van der Zee S; Vermeiren Y; Fransen E; Van Dam D; Aerts T; Gerritsen MJ; Spikman JM; van Laar T; De Deyn PP
    J Parkinsons Dis; 2018; 8(1):71-84. PubMed ID: 29480224
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.